Antiretroviral prophylaxis and the risk of cleft lip and palate: Preliminary signal detection in the food and drug administration's adverse events reporting system database

Cleft Palate-Craniofacial Journal

Volumn 49, Issue 1, 2012, Pages 118-121

  Cartsos, Vassiliki M ^a   Palaska, Pinelopi Kleio ^a   Zavras, Athanasios I ^b  

^a TUFTS UNIVERSITY SCHOOL OF DENTAL MEDICINE   (United States)

^b Combined Certificate/Masters Program Tufts University School of Dental Medicine Department of Orthodontics ^*  (United States)

Author keywords

Adverse event; Antiretroviral; Cleft; FDA; HIV; Lip; Medwatch; Offspring; Palate; Pregnancy; Prophylaxis; Reporting odds ratio; Safety

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CLEFT LIP; CLEFT PALATE; DATA ANALYSIS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PRIORITY JOURNAL; SIGNAL DETECTION; CHEMICALLY INDUCED; FEMALE; HIV INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE; PREVENTION AND CONTROL; UNITED STATES; VERTICAL TRANSMISSION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-HIV AGENTS; CLEFT LIP; CLEFT PALATE; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84855899524     PISSN: 10556656     EISSN: 15451569     Source Type: Journal    
DOI: 10.1597/10-095     Document Type: Article

References (17)

1. Ahmad SR, Freiman JP, Graham DJ, Nelson RC. Quality of adverse drug experience reports submitted by pharmacists and physicians to the FDA. Pharmacoepidemiol Drug Saf. 1996;5(1):1-7. (Pubitemid 26094121)
2. Baker R. Safety alert issued on efavirenz (Sustiva). BETA. 1998;Apr:6-7.
3. Banks D, Woo EJ, Burwen DR, Perucci P, Braun MM, Ball R. Comparing data mining methods on the VAERS database. Pharmacoepidemiol Drug Saf. 2005;14:601-609. (Pubitemid 41358695)
4. Ford N, Mofenson L, Kranzer K, Medu L, Frigati L, Mills EJ, Calmy A. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS. 2010;24:1461-1470.
5. Joao EC, Calvet GA, Krauss MR, Freimanis Hance L, Ortiz J, Ivalo SA, Pierre R, Reyes M, Heather Watts D, Read JS, NISDI Perinatal Study Group. Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study. J Acquir Immune Defic Syndr. 2010;53:176-185.
6. Kessler DA. Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA. 1993;269:2765-2768. (Pubitemid 23154251)
7. Krapels IP, Vermeij-Keers C, Müller M, de Klein A, Steegers-Theunissen RP. Nutrition and genes in the development of orofacial clefting. Nutr Rev. 2006;64:280-288. (Pubitemid 43964713)
8. Loffredo LC, Souza JM, Freitas JA, Mossey PA. Oral clefts and vitamin supplementation. Cleft Palate Craniofac J. 2001;38:76-83. (Pubitemid 32436180)
9. Rothman KJ, Moore LL, Singer MR, Nguyen US, Mannino S,Milunsky A. Teratogenicity of highvitaminAintake.NEnglJMed.1995;333:1369-1373.
10. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 2002;25:381-392. (Pubitemid 34729136)
11. Taylor GP, Low-Beer N. Antiretroviral therapy in pregnancy: a focus on safety. Drug Saf. 2001;24:683-702. (Pubitemid 32761720)
12. Townsend CL, Tookey PA, Cortina-Borja M, Peckham CS. Antiretroviral therapy and congenital abnormalities in infants born to HIV-1-infected women in the United Kingdom and Ireland, 1990 to 2003. J Acquir Immune Defic Syndr. 2006;42:91-94. (Pubitemid 43947952)
13. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in theUKand Ireland, 1990-2007. AIDS. 2009;23:519-524.
14. Watts DH, Li D, Handelsman E, Tilson H, Paul M, Foca M, Vajaranant M, Diaz C, Tuomala R, Thompson B. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr. 2007;44:299-305. (Pubitemid 46328346)
15. White A, Eldridge R, Andrews E. Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry. Acta Paediatr Suppl. 1997;421:86-88. (Pubitemid 27305104)
16. Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol. 2004;57:127-134. (Pubitemid 38223524)
17. Zucchero TM, Cooper ME, Maher BS, Daack-Hirsch S, Nepomuceno B, Ribeiro L, Caprau D, Christensen K, Suzuki Y, Machida J, et al. Interferon regulatory factor 6 (IRF6) gene variants and the risk of isolated cleft lip or palate. N Engl J Med. 2004;351:769-780. (Pubitemid 39095312)